Olli Aitio

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Acute Myeloid Leukemia

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Tero Satomaa, Henna Pynnönen, Olli Aitio, Jukka O Hiltunen, Virve Pitkänen, Tuula Lähteenmäki, Titta Kotiranta, Annamari Heiskanen, Anna-Liisa Hänninen, Ritva Niemelä, Jari Helin, Heikki Kuusanmäki, Ida Vänttinen, Ramji Rathod, Anni I Nieminen, Emrah Yatkin, Caroline A Heckman, Mika Kontro, Juhani Saarinen
Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window. Molecular cancer therapeutics (2024)
Shalom D Goldberg, Tero Satomaa, Olulanu Aina, Olli Aitio, Krista Burke, Vadim Dudkin, Brian Geist, Onyi Irrechukwu, Anna-Liisa Hänninen, Annamari Heiskanen, Jari Helin, Jukka O Hiltunen, Jacqueline Kinyamu-Akunda, Donna M Klein, Neeraj Kohli, Titta Kotiranta, Tuula Lähteenmäki, Ritva Niemelä, Virve Pitkänen, Henna Pynnönen, William Rittase, Kristen Wiley, Junguo Zhou, Juhani Saarinen
Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability. Molecular cancer therapeutics (2024)
Tero Satomaa, Henna Pynnönen, Olli Aitio, Jukka O Hiltunen, Virve Pitkänen, Tuula Lähteenmäki, Titta Kotiranta, Annamari Heiskanen, Anna-Liisa Hänninen, Ritva Niemelä, Jari Helin, Heikki Kuusanmäki, Ida Vänttinen, Ramji Rathod, Anni I Nieminen, Emrah Yatkin, Caroline A Heckman, Mika Kontro, Juhani Saarinen
Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window. Molecular cancer therapeutics 23 (8) (2024)